Skip to Content

Capricor Therapeutics, Inc.

Securities Class Action

  • Date:
  • 9/15/2025
  • Class Period:
  • FROM 10/9/2024 TO 7/10/2025
  • Status:
  • Filed
  • Filing Date:
  • 7/17/2025
  • Court:
  • U.S. District Court: District of Southern California

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:CAPR) in the United States District Court Southern District Of California on behalf of all persons and entities who purchased or otherwise acquired Capricor securities between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”). Investors have until September 15, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
According to the complaint, defendants provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.
 
On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application.
 
Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025.
Contact Instructions
Please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com with any questions regarding the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in . BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: